Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.04	$1.96	$1.41 ▼ $2.79	$92.72M	1.46	67,103 shs	55,335 shs
GLUE Monte Rosa Therapeutics	$5.90 +5.2%	$4.62	$3.50 ▼ $12.40	$345.07M	1.41	1.09 million shs	392,238 shs
OCGN Ocugen	$1.00 -3.8%	$0.96	$0.52 ▼ $1.80	$303.71M	4.18	4.57 million shs	4.31 million shs
RCKT Rocket Pharmaceuticals	$3.34 +16.8%	$3.73	$2.19 ▼ $26.98	$305.41M	0.67	2.31 million shs	12.35 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	0.00%	+11.17%	-0.78%	+13.97%	+7.94%
GLUE Monte Rosa Therapeutics	+5.17%	+12.17%	+29.10%	+29.67%	+24.47%
OCGN Ocugen	-3.85%	-13.04%	-8.26%	+47.19%	-45.36%
RCKT Rocket Pharmaceuticals	+16.78%	+5.70%	+22.79%	-47.24%	-85.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTX Entera Bio	2.9359 of 5 stars	3.5	5.0	0.0	3.3	0.8	0.0
GLUE Monte Rosa Therapeutics	2.1963 of 5 stars	3.3	1.0	0.0	3.3	1.7	0.6
OCGN Ocugen	1.3955 of 5 stars	3.5	1.0	0.0	2.7	0.0	0.0
RCKT Rocket Pharmaceuticals	4.8555 of 5 stars	4.2	3.0	4.7	1.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	3.00	Buy	$10.00	390.20% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	159.89% Upside
OCGN Ocugen	3.00	Buy	$6.00	500.00% Upside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	456.89% Upside

Current Analyst Ratings Breakdown

Latest ENTX, RCKT, OCGN, and GLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$180K	515.10	N/A	N/A	$0.23 per share	8.87
GLUE Monte Rosa Therapeutics	$75.62M	4.80	N/A	N/A	$3.63 per share	1.63
OCGN Ocugen	$4.05M	72.11	N/A	N/A	$0.10 per share	10.00
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$9.54M	-$0.26	N/A	N/A	N/A	-4,525.11%	-95.10%	-82.77%	8/8/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	73.76	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/14/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest ENTX, RCKT, OCGN, and GLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	N/A	N/A	N/A	$7.23 million	N/A
8/14/2025	Q2 2025	OCGN Ocugen	-$0.06	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	ENTX Entera Bio	-$0.11	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/9/2025	Q1 2025	ENTX Entera Bio	-$0.07	-$0.06	+$0.01	-$0.06	N/A	$0.04 million
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	13.07	13.07
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61
OCGN Ocugen	1.74	2.60	2.60
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
GLUE Monte Rosa Therapeutics	79.96%
OCGN Ocugen	10.27%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.38%
GLUE Monte Rosa Therapeutics	6.90%
OCGN Ocugen	4.42%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	20	45.45 million	40.73 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.27 million	Optionable
OCGN Ocugen	80	292.03 million	279.12 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

ENTX, RCKT, OCGN, and GLUE Headlines

Recent News About These Companies

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 17 at 6:05 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

July 17 at 4:15 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 17 at 4:00 PM | globenewswire.com

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action– Hagens Berman

July 17 at 3:07 PM | globenewswire.com

Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals stock surges after FDA grants key designation

July 17 at 1:42 PM | investing.com

Rocket Pharmaceuticals Shares Jump After FDA Grants Accelerated Review Status to Gene Therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 17 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 17 at 10:00 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKT

July 17 at 9:00 AM | prnewswire.com

NASDAQ: RCKT INVESTOR ALERT: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors of August 11, 2025 Deadline

July 17 at 8:36 AM | globenewswire.com

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

July 17 at 7:00 AM | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Brokerages

July 17 at 2:46 AM | marketbeat.com

B2B Rocket joins publicly traded tech powerhouse in move to scale smarter and faster

July 16 at 5:38 PM | manilatimes.netM

Virgin Islands Students Complete Elite NASA-Style Training at U.S. Space & Rocket Center

July 16 at 5:38 PM | viconsortium.comV

Army Unit in Hawaii Receives Long-range Rocket Artillery for Pacific Operations

July 16 at 5:38 PM | news.usni.orgN

Rocket Pharmaceuticals, Inc. (RCKT) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights

July 16 at 4:44 PM | globenewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 16 at 4:03 PM | prnewswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

July 16 at 12:59 PM | globenewswire.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

July 16 at 11:03 AM | globenewswire.com

Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

July 16 at 9:15 AM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, RCKT, OCGN, and GLUE Company Descriptions

Entera Bio NASDAQ:ENTX

$2.04 0.00 (0.00%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$2.04 0.00 (-0.25%)

As of 07/17/2025 07:13 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Monte Rosa Therapeutics NASDAQ:GLUE

$5.90 +0.29 (+5.17%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$5.89 -0.01 (-0.17%)

As of 07/17/2025 06:10 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Ocugen NASDAQ:OCGN

$1.00 -0.04 (-3.85%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$1.01 +0.01 (+1.00%)

As of 07/17/2025 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.34 +0.48 (+16.78%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$3.32 -0.02 (-0.75%)

As of 07/17/2025 07:56 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time